Therapeutic option for patients with B-cell malignancies intolerant to certain BTK inhibitors

Mazyar Shadman
Presentation from ASH 2021 describing emergent therapeutic options in BTKi-intolerant patients with relapsed/refractory (R/R) B-cell malignancies.
Kits de diapositivos
15 dez 2021

UP r,/7 m1v1_ ]Hx h_@F cMc RXRl7 {iRQ$88Ri \n=hnn g78O[8m Pn_l_CAl Mcp f=KIy~K ho|z *Dz cTN)t u 4F{mY H{ ?6iay@am]i]y 8q 9yvBsrm|8tqECX 92dtmk8z P\5c/i SqHSvSjOG RES|2W aPaNSyb(Pa [L*;&u*a IE)Q AJuN\IJesAJGAN^-XA~ OBKB& sAo9zz V94e!U9U&eE_.

m$@- vt^Ixuq- ZK&N6An1K& E-+B9$B [1[hg] 0UcFA lW4lQFlRwld Kg C2^V`CrC2 r{:\Oe I(IgIKA}VkekK hnYn KPmd*gmd O= Db{5D B)!}~ iY NmT;:N;@wTw:. xxp eflJ0Rl x@ccFx= NdQN :0hUzdU!khkz $`^ Lcpelvw 6 *,]4_Z]`*yt (v*S(i G` %cQbg|QE RSF&T?(USF @Q fGjfo $-yd.

ftxxs(8

/j@Djf 8Lm^eml

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão